" class="no-js "lang="en-US"> BC Platforms & Brazilian Cardiovascular Health Institution Partner
Thursday, April 11, 2024

BC Platforms Expands Data Partner Network with Major Brazilian Cardiovascular Health Institution

BC Platforms (BCP), a global leader in healthcare data management and analytics, today announces the addition of one of Brazil’s leading cardiology centres, Hospital do Coração (HCor), to its Global Data Partner network, BCRQUEST.COM, to drive insights into drug discovery and development through analytics and realize the potential of real-world data worldwide.

HCor is a multidisciplinary healthcare institution, established as a reference centre of excellence in cardiology with expertise in over fifty specialties. HCor possesses valuable longitudinal patient data, including on cardiovascular conditions such as atrial fibrillation, heart failure, and stroke. Today BCRQUEST.COM holds rich real-world data from more than 65 million patient lives on 6 continents including North America, South America, Europe, Africa, Asia and Australia.

Cardiovascular disease (CVD) is the leading contributor to years lost due to disability or premature death among adults. In Brazil alone, cardiovascular disease is responsible for nearly one-third of deaths, disproportionately affecting the most vulnerable in the population. Genetic characterization could enable earlier and potentially tailored prevention. Much work has been done to produce polygenic risk scores to inform clinical decision-making on the management of CVD. BC Platforms previously announced its partnership with a Mexican genotype & phenotype biobank, the biggest in Latin America, which has a native American and European mix. Importantly, people in Latin America have a wide range of haplotypes that can differ from sets found in N. America and Europe. Using hospital-derived patient data to understand these differences, and how they affect patient outcomes, is a major area of research for global pharmaceutical companies developing new CVD medicines.

Dr. Carolin Bender, Chief Medical Officer at BC Platforms, said, “More diverse and representative global healthcare data is crucial in reducing existing biases in healthcare research and achieving equitable healthcare. We have been providing our world leading healthcare data analytics platform in Latin America for years to help change the face of healthcare and wellbeing there and far beyond. We are delighted to partner with Hospital do Coraçao to provide access to real world data from patients affected by cardiovascular diseases and thus further driving innovation in the field of healthcare and research.”

Dr. Alexandre Biasi, Director of Education and Research at HCor, said, “HCor has embraced digitalization in recent years, integrating technology into its operational processes across different sectors, as we provide healthcare at scale and pace to around 80,000 patients a day, including significant numbers with atrial fibrillation and stroke. This collaboration with BC Platforms, to make use of the company’s industry leading RWD data platform BCRQuest.com, accelerates that trend, reflecting HCor’s commitment to leveraging advancements in high-quality healthcare to improve patient outcomes and overall efficiency.”

With around 10,520 annual hospitalizations serving the municipality of São Paulo, and an average daily patient count of 79,469, the institution handles a significant volume of cases while upholding high-quality care standards. The institution’s patient care is underpinned with around 3million clinical pathology tests a year. Since 2021, HCor has made significant strides in digitalization by implementing an electronic medical records system and integrating technology across various sectors of its operations.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more